A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy.

The article discusses a Phase 3 clinical trial comparing the overall survival of participants with metastatic castration-resistant prostate cancer receiving xaluritamig versus cabazitaxel or second androgen receptor-directed therapy. The trial aims to enroll 675 participants and is set to be completed by November 2029. The study focuses on various outcome measures, including overall survival, radiographic progression-free survival, and objective response rate, among others. The trial is interventional, with a randomized allocation and parallel intervention model, and is being conducted by Amgen. [Extracted from the article]